



IBA receives an offer from a leading financial consortium to develop its Bioassays business.

Louvain-la-Neuve, May 27, 2010

Louvain-la-Neuve, Belgium, May 27 2010 – IBA (Ion Beam Applications SA) has announced that it will review an offer received from a leading financial consortium. The Group considers the consortium's offer to participate in the Bioassays project for 60%, a serious one and potentially attractive.

"We have decided to consider this offer seriously because we think that it may offer the Bioassays division the framework and resources it needs to achieve its potential, in which we believe strongly," Pierre Mottet, CEO of the Group, said.

If IBA's Board of Directors approves the deal and an agreement is signed at the end of the due diligence and legal personnel representative's consultation period, it would provide funding for this promising business area, plus a structure appropriate to its growth potential and development strategy.

IBA's Bioassays division is active in the field of in vitro diagnostics. It is also involved in the in vitro screening of new drugs for the pharmaceutical and biotech industries, thanks to its HTRF[®] technology. While in vitro screening technologies are outside IBA's core business, IBA wishes to continue to participate actively in this high growth market. Under the terms of the offer, IBA would remain a major player in Bioassays, with a 40 percent stake in its capital.

Invitation to a conference call

IBA holds a conference call for media representatives, analysts and investors in English on 28 May 2010, at **5:45 p.m.** CET. Please dial in ten minutes before the conference call starts using the following dial-in numbers:

- +44 203 003 2666 (International access number)
- 0800 746 68 (Belgium free)
- 0805 630061 (France free)
- 0800 673 7932 (Germany free)
- 1 866 966 5335 (USA free)

Password to give to the operator: IBA GROUP



About IBA

IBA (<http://www.iba-worldwide.com>) develops and markets leading edge technologies, pharmaceutical products, and tailor-made solutions for healthcare with a focus on cancer diagnosis and treatment. Leveraging its scientific expertise, IBA is also active in the field of sterilization and ionization.

IBA is listed on the pan-European stock exchange and included in the BelMid Index. (IBA : Reuters IBAB.BR and Bloomberg IBAB.BB).

Contact

IBA

Jean-Marc Bothy
Chief Financial Officer
Tel.: +32 10 47 58 90

InvestorRelations@iba-group.com